ReviewNeurologia medico-chirurgica2018
Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma.
Review in Neurologia medico-chirurgica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 182 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
182 citing papers in PubMed, 2 syntheses or guidelines pooled it, 324 citations in OpenAlex.
- RNA Expression Signatures in Glioblastoma: A Systematic Review of Tumour Biology and Therapeutic Targets.Oncology research · 2025Pooled it
- Bibliometric and visualization analysis in the field of epigenetics and glioma (2009-2024).Frontiers in oncology · 2024Pooled it
- Reprogramming temozolomide response in glioblastoma through regulated and immunogenic cell death modalities.Cell death discovery · 2026Review
- Anti-glioma mechanism of Angelica sinensis and stigmasterol: p53-associated ferroptosis identified via multi-method analysis.Scientific reports · 2026Article
- Dual suppression of stemness and redox adaptation in glioblastoma through filaggrin upregulation by an abiraterone-based HDAC inhibitor.Journal of biomedical science · 2026Article
- Natural Product 4-Acetylantroquinonol B Enhances NK Cell-Mediated Immunity Against Glioblastoma.Cancer medicine · 2026Article
- Cinobufotalin reduces glioblastoma resistance to temozolomide by inhibiting the CCL5-mediated PI3K/Akt/mTOR signaling pathway.Translational cancer research · 2026Article
- RFC4 drives temozolomide resistance in glioblastoma by activating STK38-BECN1-dependent autophagy.Nature communications · 2026Article
- The Time-Dependent Effects of Temozolomide on Autophagy Gene Expression in Glioblastoma Cells.Biomedicines · 2026Article
- Valproic acid reverses macrophage-mediated temozolomide resistance in macrophage-rich gliomas.NPJ precision oncology · 2026Article
- Mesoporous silica nanoparticles in glioblastoma: smart nano-platforms for targeted therapy and precision diagnosis.3 Biotech · 2026Review
- The evolution of chemotherapy in brain tumors: from historical milestones to precision medicine in glioblastoma.Exploration of targeted anti-tumor therapy · 2026Review
- MicroRNAs as the critical regulators of ubiquitin-proteasome system through F-box protein targeting during tumor progression.Cancer cell international · 2025Review
- Synergistic Cancer Metabolic Therapy via Co-Delivery of 3-Bromopyruvate and Temozolomide with a Supramolecular Shuttle.ACS applied materials & interfaces · 2025Article
- Emerging trends in cell-based therapies: contemporary advances and ethical considerations in translational neurosurgical oncology.Journal of neuro-oncology · 2025Review
- Anti-miRNA- 155 - 5p enhances the cytotoxic efficacy of temozolomide in brain cancer stem cells.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Review
- Development of AGT-7: An InnovativePharmaceuticals (Basel, Switzerland) · 2025Article
- Stem cell therapies and glioma stem cells in glioblastoma: a systematic review of current challenges and research directions.International journal of emergency medicine · 2025Review
- Association of Hsa_circ_0059511 with the sensitivity of the temozolomide chemotherapeutic treatment in human glioma cells.Scientific reports · 2025Article
122 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is a highly malignant type of primary brain tumor with a high mortality rate. Although the current standard therapy consists of surgery followed by radiation and temozolomide (TMZ), chemotherapy can extend patient's post-operative survival but most cases eventually demonstrate resistance to TMZ. O
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.